BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 17, 2014
View Archived Issues
Third milestone achieved in GenVec and Novartis collaboration
Read More
UCB and MRC Technology sign exclusive license agreement
Read More
Preclinical characterization of a novel N-glucoside SGLT2 inhibitor
Read More
Shire reviews activities of fourth quarter 2013
Read More
Investigators identify a potential prognostic marker for CRPC
Read More
Sato Pharmaceutical discloses new SLC22A12 inhibitors
Read More
Novel GPR119 receptor agonists patented
Read More
Results presented from phase I study of ridaforolimus and vorinostat in RCC
Read More
Endo Pharmaceuticals discloses new agents for cancer
Read More
Soligenix receives grant from NIAID to support development of SGX-943 for melioidosis
Read More
Scientists at Sunshine Lake Pharma synthesize novel NS5A inhibitors
Read More
Japanese researchers claim new prostanoid EP1 receptor antagonists
Read More
FDA issues complete response letters regarding sNDAs for Xarelto
Read More
Proximagen designs new PAR-2 antagonists
Read More
ViroMed granted FDA orphan drug designation for VM-202-ALS, launches phase I/II trial
Read More
New PHD2 inhibitors presented by Taisho Pharmaceutical for anemia
Read More
EpiTherapeutics prepares and tests novel KDM5 inhibitors
Read More
Novel Ca(v)3.2. blockers disclosed by Kyowa Hakko Kirin
Read More
Oxford BioMedica and Sanofi amend terms of agreement for gene-based ocular disease drugs
Read More
Cangene shareholders in favor of acquisition
Read More
Forest Laboratories to discontinue sale of Namenda tablets
Read More
NCI and FDA reach SPA agreement for phase III trial of Syndax's entinostat
Read More
Phase III study of mepolizumab in eosinophilic granulomatosis with polyangiitis begins
Read More
European COMP recommends orphan drug designation for ISIS-TTRRx
Read More
Millennium Pharmaceuticals to conduct PET imaging study of [68Ga]MLN-6907
Read More
FDA approves BioMarin's Vimizim for MPS IVA
Read More